Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 12/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505195 | 0.86 | F10 (0.45) | CYP11B2F10DRD2DRD4MAP3K11 | |
| SCHEMBL8268238 | 0.72 | F10 (0.43) | F10ALDH1A1 | |
| SCHEMBL8267982 | 0.71 | F10 (0.48) | F10 | |
| SCHEMBL5395497 | 0.71 | F10 (0.43) | F10HRH3 | |
| SCHEMBL16361760 | 0.70 | CYP3A4 (0.43) | F10ALDH1A1 | |
| SCHEMBL1028976 | 0.70 | F10 (0.45) | F10 | |
| SCHEMBL8262173 | 0.70 | F10 (0.47) | F10 | |
| SCHEMBL4656327 | 0.70 | F10 (0.52) | F10 | |
| SCHEMBL4627021 | 0.70 | F10 (0.46) | F10 | |
| SCHEMBL5626795 | 0.69 | CYP11B2 (0.45) | CYP11B2DRD2DRD4MAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1196412-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6716841-B2 | SUCH AS 1-((1-(3-(AMINOMETHYL)PHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-5-YL)CARBONYL) -5-(2-( AMINOSULFONYL)PHENYL)-2,3-DIHYDRO-1H-INDOLE FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS; ANTICOAGULANTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2003-05-22 | — | — | US | disclosed |
| US-6429205-B1 | ANTICOAGULANTS | BRISTOL-MEYERS SQUIBB PHARMA COMPANY | 2002-08-06 | — | — | US | disclosed |
| EP-1196412-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005784-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096820-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | SERPINC1, CTRB1, F2 | CYP11B2 2168/4885F10 25/4885DRD2 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.